Completed Research Grants
Dr. Mark Cooper, Institute of Neurology, Dept of Clinical and Movement Neurosciences, University College London, London, England
The Influence of TRIM11on Tau, Aggregation, Release and Propagation
Dr. Todd J. Cohen, The University of North Carolina at Chapel Hill, NC
Uncovering Unique Tau Profiles That Distinguish PSP From Other Tauopathies
Dr. Lukasz Joachimiak, Center for Alzheimer’s and Neurodegenerative Diseases, UT Southwestern Medical Center, Dallas, TX
Structural Basis for Tau Strain Conformation in CBD and PSP
Dr. Geidy E. Serrano, Banner Sun Health Research Institute, Sun City, AZ
Single-Whole-Cell Characterization in Progressive Supranuclear Palsy
Dr. Kenneth Matthew Scaglione, Molecular Genetics and Microbiology, Duke University, Durham, NC
Small Molecule Regulation of a Protein Quality Control E3 to Treat PSP
Dr. Tsuneya Ikezu, Boston University School of Medicine, Boston, MA
Evaluation of STX6 silencing on the novel AAV-based PSP mouse model
Dr. Lars Ittner, University of New South Wales, Australia
Defining a Novel Drug Target for PSP and CBD
Dr. John W. Steele, Humboldt State University, Arcata, CA
iCRISPRi in Human Neurons and Glia to Elucidate Selective Turnover of Tau
Dr. Jori Fleisher, Rush University, Chicago, IL
Care Where it Counts; Support to Reduce Isolation and Ensure Well-Being for Patients and Caregivers
Dr. Michelle S. Troche, Columbia University, New York, NY
The Stephen N. Jasperson Study: Developing Treatments for Swallowing and Communication Deficits in PSP
Dr. Edward A. Burton, University of Pittsburgh, PA
Functional Evaluation of PSP GWAS Genes in a Tauopathy Model In-Vivo
Dr. Xiaobo Mao, The Johns Hopkins University School of Medicine, Baltimore, MD
The Role of TTR1 in Mediating Tau Spread In-Vitro and In-Vivo
Dr. Thomas Koeglsperger, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Munich, Germany
Investigating the Role of Syntaxin 6 (STX6) for Tau Protein Cell-to-Cell Transmission
Dr. Monica Y. Sanchez-Contreras, University of Washington, Seattle, WA
The Sarah Boone Nesbitt Study: Oxidative damage and gene deregulation in PSP and related disorders
Dr. Kathryn Bowles, Mount Sinai School of Medicine, New York, NY
Understanding MAPT Sub-Haplotypes and Alternative Splicing
Dr. Natura Myeku, Columbia University, New York, NY
Testing Phosphodiesterase Inhibitors for Treatment of Tauopathy Disorders
Dr. Haung (Ho) Yu, Columbia University, New York, NY
The Stephen N. Jasperson Study: Small Molecule Activators of Phospholipase D and Tau Clearance via Autophagic Flux
Dr. Gal Bitan, University of California Los Angeles, CA
Small-Molecule Modulation of Tau Clearance and Aggregation
Dr. Stewart Clark, State University of New York, Buffalo, NY
The Establishment of a Preclinical Model for Progressive Supranuclear Palsy
Dr. Brittany Dugger, University of California San Francisco, CA
Tau in Peripheral Tissues of PSP and CBD
Dr. Shona Joy, Neural Stem Cell Institute, Albany, NY
Disease in a dish model of PSP
Ragnhildur Thora Karadottir, PhD, University of Cambridge
Characterization of Tau and Its Pathology in Oligodendrocytes Derived from Induced Pluripotent Stem Cells from Patients with PSP-like Phenotype
Michael D. Geschwind, MD, PhD, University of California San Francisco
A Review and Proposal for New Research Studies on Guam and in Umatac Village, 2013: Assessment of Guam PDC/ALS in 2013-2014
Aimee Kao, PhD, University of California San Francisco
Understanding the Relative Contributions of Genetic Risk Factors in PSP
Rohan De Silva, PhD, University College, London
MOBP, STX6 & EIF2AK3 Expression and Distribution in PSP Brains
Daniel C. Lee, PhD, University of South Florida, Tampa
Impact of Arginase1 Over-Expression and SAT1 Deficiency during Tauopathies
Mina Botros, Boston University
Development of New PSP Mouse Model
Rakez Kayed, PhD, University of Texas, Galveston
Specific Targeting of PSP Brain-Derived Tau Oligomers
Dr. Adam Gerstenecker, University of Alabama, Birmingham
Investigating Functional Ability in PSP
| 2016 | Consensus conference for the revision of the diagnostic criteria of PSP | Dr. | Guenter | Hoeglinger | Klinikum rechts der Isar der TU Muenchen, Munich, Germany |
| 2014 | Elucidating PSP Genotype-Phenotype Relationships Using Human Isogenic iPSCs | Dr. | John | Steele | University of California, San Diego, CA |
| 2014 | Synaptic Tau-Proteasome Dysfunction and a Potential Therapeutic Strategy | Dr. | Natura | Myeku | Columbia University, New York, NY |
| 2013 | Epigenetic Modifications in PSP | Dr. | Ulrich | Mueller | University of Giessen, Germany |
| 2014 | Spreading of a Synuclein Pathology in Multiple System Atrophy | Dr. | Johannes | Brettschneider | University of Ulm, Germany |
| 2014 | Selective Cell Vulnerability in MSA | Dr. | Eduardo | Benaroch | Mayo Clinic , Jacksonville, FL |
| 2013 | Urso Student Fellowship | Mr. | John | Titus | Duke University Medical Center, Durham, NC |
| 2013 | The Role of O-Linked Protein Glycosylation in the Spread of Tau Pathology | Dr. | Christoph | Wiessner | Asceneuron SA, Switzerland |
| 2013 | Altering Tau Splicing for PSP and Other 4R Tauopathies | Dr. | Michael | Wolfe | Harvard Medical School, Boston, MA |
| 2013 | Follow-Up Genotyping & Functional Analysis of PSP H1 Haplotype Variants | Dr. | Pau | Pastor | Foundation for Applied Medical Research, Pamplona, Spain |
| 2013 | Eloise H. Troxel Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic , Jacksonville, FL |
| 2013 | Urso Student Fellowship | Mrs. | Emily | Beiser | Rutger University, New Brunswick, NJ |
| 2013 | Mechanisms and Therapy for Tauopathy based on RNA Binding Proteins | Dr. | Benjamin | Wolozin | Boston University, Boston, MA |
| 2013 | Tau Dimerization: A Mechanism of Tau Function and Dysfunction? | Dr. | Stuart | Feinstein | University of California, Santa Barbara, CA |
| 2012 | PSP Whole Exome Study Phase Two | Dr. | Gerad | Schellenberg | University of Pennsylvania, Philadelphia, PA |
| 2012 | Splice Variant Markers for PSP | Dr. | Judith | Potashkin | Rosalind Franklin University of Medicine and Science |
| 2012 | Eloise H. Troxel Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic , Jacksonville, FL |
| 2012 | Tracking Progressive Neurodegeneration in PSP Using Diffusion Tensor MRI | Dr. | Massimo | Filippi | Vita-Salute San Raffaele University, Milan, Italy |
| 2012 | Identifying Functional Genetic Risk Factors for PSP by RNA-seq | Dr. | Nilufer | Ertekin-Taner | Mayo Clinic, Jacksonville, FL |
| 2012 | Gene Expression and Neuropathology Endophenotypes for Gene Discovery in PSP | Dr. | Nilufer | Ertekin-Taner | Mayo Clinic, Jacksonville, FL |
| 2012 | Mechanisms of Tau and ER Stress for Novel PSP and CBD Therapeutics | Dr. | Jose | Abisambra | University of South Florida, Tampa, FL |
| 2012 | An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to the AL-108-231 of Davunetide for the Treatment of Non-PSP Predicted Tauopathies: CBD, Progressive Nonfluent Aphasia and FTD with Parkinsonism Linked to Chromosome 17 | Dr. | Adam | Boxer | University of California, San Francisco, CA |
| 2012 | PSP Whole Exome Study | Dr. | Gerard | Schellenberg | University of Pennsylvania, Philadelphia, PA |
| 2011 | Eloise H. Troxel Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic, Jacksonville, FL |
| 2011 | Models to Determine the Toxicity of Tau Aggregates | Dr. | Chris | Gamblin | University of Kansas, Lawrence, KS |
| 2011 | Evaluating Reduced Tau Levels as a Therapy for PSP and CBD | Dr. | Timothy | Miller | Washington University School of Medicine, St. Louis, MO |
| 2011 | Epigenetic Modifications in PSP | Dr. | Ulrich | Mueller | University Hospital Giessen & Marburg, Giessen, Germany |
| 2011 | CHIP-Mediated Regulation of Hsp90 High Affinity Complex | Dr. | Leonard | Petrucelli | Mayo Clinic, College of Medicine, Jacksonville, FL |
| 2011 | Manipulating the Substrate Specificity Program in the Chaperone System to remove Tau in PSP and CBD | Dr. | Chad | Dickey | University of South Florida, Tampa, FL |
| 2010 | A Pilot Clinical Trial of NAP (AL-108) for CBD and Frontotemporal Lobar Degeneration with Predicted CBD Pathology | Dr. | Adam | Boxer | Regents of the University of California, San Francisco, CA |
| 2010 | Pathogenetic Mechanisms of Progressive Supranuclear Palsy and Corticobasal Degeneration | Dr. | Gerard | Schellenberg | University of Pennsylvania, Philadelphia, PA |
| 2010 | PSP/CBD Genome-Wide Association Analysis follow-up and replication | Dr. | Gerard | Schellenberg | University of Pennsylvania, Philadelphia, PA |
| 2010 | Eloise H. Troxel Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic, Jacksonville, FL |
| 2010 | Tau and its Pathology in Neurons derived from Induced Pluripotent Stem Cells of FTDP-17T Patients with PSP-Like Tau Pathology | Dr. | Maria | Spillantini | University of Cambridge, Cambridge, UK |
| 2010 | Autophagic Modulation and Clearance of Tau Aggregates | Dr. | Ho | Yu | Columbia University Medical Center, New York, NY |
| 2009 | Modeling Haplotype-Specific Gene Function at the MAPT Locus in 4R Tauopathy | Dr. | Richard | Wade-Martins | University of Oxford, Oxford, UK |
| 2009 | Inhibition of Tau Pathology in Transgenic Mouse Models with an Optimized Orally Active Tau Kinase Inhibitor | Dr. | Hanno | Roder | TauTaTis, Inc, Jacksonville, FL |
| 2009 | MicroRNA Regulation of MAPT in CBD and Related Tauopathies | Dr. | Rosa | Rademakers | Mayo Clinic Jacksonville, FL |
| 2009 | Structural Polymorphism of Tau Filaments in CBD | Dr. | Martin | Margittai | University of Denver, Denver, CO |
| 2009 | Comparative Proteomics of CBD & PSP Brain to Identify Biomakers | Dr. | Shu-Hui | Yen | Mayo Clinic, Jacksonville, FL |
| 2009 | Development of Activators of Puromycin Sensitive Aminopeptidase to Treat CBD | Dr. | Stanislav | Karsten | Los Angeles Biomedical Research Institute, Torrance, CA |
| 2009 | Tau-Mediated Effects Upon Microtubule Structure and Kinesin Translocation | Dr. | Stuart | Feinstein | Regents of the University of California, Santa Barbara, CA |
| 2009 | In Vivo Identification of Pharmacological Treatments for Tauopathy | Dr. | Mel | Feany | Brigham and Women’s Hospital, Boston, MA |
| 2009 | HSP-Peptide Complex Mediated Immunization in a Mouse Model of Tauopathy | Dr. | Michael | DeTure | Mayo Clinic Jacksonville, FL |
| 2009 | Genomewide Identification of Transregulators of Tau Gene Expression & Splicing | Dr. | Rohan | deSilva | Institute of Neurology, UCL, Queen Square, London |
| 2009 | A Pilot Clinical Trial of NAP (AL-108) for CBD and Frontotemporal Lobor Degeneration with Predicted CBD Pathology | Dr. | Adam | Boxer | Regents of the University of California, San Francisco, CA |
| 2009 | Polyphenols from Grape Seeds as a Potential Therapeutic Agent in Taupathies | Dr. | Giulio | Pasinetti | Mount Sinai School of Medicine, New York, NY |
| 2009 | The Effects of CBD-Associated Tau Gene H1 Haplotype on Tau Expression | Dr. | Hana | Dawson | Duke University Medical Center, Durham, NC |
| 2009 | Targeting Hsp70 as a Therapeutic Strategy for CBD and Other Taupathies | Dr. | Chad | Dickey | University of South Florida, Tampa, FL |
| 2009 | The Role of Microglial-Meditated Neuroinflamation in Fronto-Temporal Dementia Tau Pathology | Dr. | Kiran | Bhaskar | Cleveland Clinic, Clevelnd, OH |
| 2009 | Eloise H. Troxel Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic, Jacksonville, FL |
| 2008 | Unilateral Pedunculopontine Deep Brain Stimulation in PSP | Dr. | Elena | Moro | University of Toronto, Toronto, ON |
| 2008 | Noninvasive Cortical Stimulation for Motor and Non-Motor Features of PSP and CBD | Dr. | Alan | Wu | University of California, Los Angeles, CA |
| 2008 | Toward a Molecular Understanding of Tau Misfolding | Dr. | Martin | Margittai | University of Denver, Denver, CO |
| 2008 | Phenotypic Characterization of Tauopathy Zebrafish | Dr. | Edward | Burton | University of Pittsburgh, Pittsburg, PA |
| 2008 | Mapping Progressive Neurodegeneration in PSP using Transcranial Magnetic Stimulation and CSF-Tau | Dr. | David | Williams | Monash University, Australia |
| 2007 | Genome-Wide Association Study in PSP | Dr. | Dennis | Dickson | Mayo Clinic College of Medicine, Jacksonville, FL |
| 2007 | Genome-Wide Association Study in PSP | Dr. | Rohan | deSilva | Institute of Neurology, UCL, Queen Square, London |
| 2007 | Genome-Wide Association Study in PSP | Dr. | Ulrich | Müller | University Hospital, Giessen, Germany |
| 2007 | Genome-Wide Association Study in PSP | Dr. | Hank | Hakonarson | Center for Applied Genomics, Philadelphia, PA |
| 2007 | Genome-Wide Association Study in PSP | Dr. | Bernie | Devlin | University of Pittsburgh, Pittsburg, PA |
| 2007 | Genome-Wide Association Study in PSP | Dr. | Gerard | Schellenberg | Geriatric Research Education and Clinical Center, Seattle, WA |
| 2007 | Longitudinal Prospective PSP Study | Dr. | Irene | Litvan | University of Louisville Health Sciences Center, Louisville, KY |
| 2007 | Haplotype regulation of alternative splicing at the MAPT locus | Dr. | Richard | Wade-Martins | University of Oxford, United Kingdom |
| 2007 | Unraveling Multi-Protein Chaperone Complexes in PSP and other Tauopathies | Dr. | Chad | Dickey | University of South Florida, Tampa, FL |
| 2007 | Genome-Wide Association Study in PSP | Dr. | Ulrich | Muller | University Hospital, Giessen, Germany |
| 2007 | Inhibition of Tau Pathology in Transgenic Mouse Models with an Optimized Orally Active Tau Kinase Inhibitor | Dr. | Hanno | Roder | Mayo Clinic, Jacksonville, FL |
| 2007 | Strength Training Patients with PSP for Dysphagia | Dr. | Christine | Sapienza | University of Florida, Gainesville, FL |
| 2007 | Tau Aggregation in Oligodendrocytes and the Role of Thrombin Signaling | Dr. | Christine | Richter-Landsberg | University of Oldenburg, Germany |
| 2006 | Parkin and Tau Mutational Effects on Tangle Formation in PSP | Dr. | Parvoneh | Navas | University of Washington School of Medicine, Seattle, WA |
| 2006 | Finemapping of Risk Loci for PSP Identified in a Genome-Wide Scan | Dr. | Michael | Hutton | Mayo Clinic College of Medicine, Jacksonville, FL |
| 2006 | Interaction of Neuronal and Glial Tau in a Drosophila Model of Tauopathy | Dr. | Mel | Feany | Brigham and Women’s Hospital, Boston, MA |
| 2006 | Hypothesis- Driven Gene Profiling in an Animal Model of PSP | Dr. | Ronald | Klein | LSU Health Sciences Center, Shreveport, LA |
| 2006 | Studies of PSA Neuroprotective Role Using Transgenic Mouse Models | Dr. | Stanislav | Karsten | University of California, Los Angeles, CA |
| 2005 | AKT-Dependent Signaling in PSP and Transgenic Mouse Model of Tauopathy | Dr. | Hanna | Ksiezak-Reding | Mount Sinai School of Medicine, New York, NY |
| 2005 | Eloise H. Troxel Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic, Jacksonville, FL |
| 2005 | Inhibiting Transglutaminase Splice Variants for Treatment of PSP | Dr. | Nancy | Muma | Loyola University Chicago, Maywood, IL |
| 2005 | Do PSP Associated TAU Polymorphisms Alter the Expression of the TAU Microtubule Binding Domain | Dr. | Hana | Dawson | Duke University Medical Center, Durham, NC |
| 2005 | Effect of Coenzyme Q10 in PSP: A Randomized, Multicenter, Placebo-Controlled, Double Blind Study | Dr. | Diana | Apetauerova | Lahey Clinic, Burlington, MA |
| 2005 | Proteomics Analysis of a Novel Murine Model of Astrocytic Tau Pathology in PSP | Dr. | Mark | Forman | University of Pennsylvania School of Medicine, Philadelphia, PA |
| 2005 | A Zebrafish Model of Tauopathy | Dr. | Edward | Burton | University of Pittsburgh, Pittsburgh, PA |
| 2004 | PSP and a Failing Ubiquitin-Proteasome System | Dr. | FW | van Leeuwen | Netherlands Institute for Brain Research, The Netherlands |
| 2004 | Identification of Compounds that Modulate Exon 10 Splicing in the Tau Gene | Dr. | Jianhua | Zhou | University of Massachusetts Medical School, Worcester, MA |
| 2004 | Proteomis Analysis of Post Mortem PSP Brain | Dr. | Benoit | Giasson | University of Pennsylvania, Philadelphia, PA |
| 2004 | Heat Shock Proteins as Inhibitors of Tau Aggregation in Oligodendrocytes | Dr. | Christine | Richter-Landsberg | University of Oldenburg, Germany |
| 2004 | Proteomic Analysis of a Transgenic Mouse Model of Tauopathy | Dr. | Shu-Hui | Yen | Mayo Clinic, Jacksonville, FL |
| 2004 | Assessment of Tau Protein Isoform profiles in Cerebrospinal Fluid of Tauopathy Patients as a Potential Diagnostic Biomarker | Dr. | Rohan | de Silva, | University College London, London, UK |
| 2001 | Eloise H. Troxel Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic, Jacksonville, FL |
| 2003 | Parkin Mutations in a Mouse Model of PSP | Dr. | Parvoneh | Navas | University of Washington School of Medicine, Seattle, WA |
| 2003 | Correlation of Clinical Severity, Brain Inflammatory Changes & Apparent Water Diffusion Coefficients in PSP & Idiopathic Parkinson’s Disease | Dr. | David | Brooks | Imperial College School of Medicine London, UK |
| 2003 | Discovery of Tau Phosphorylation Inhibitors for the Treatment of PSP | Dr. | Kenneth | Kosik | Brigham and Women’s Hospital, Boston, MA |
| 2003 | Cystamine, a Transglutaminase Inhibitor, for the Treatment of Tauopathies, Especially in PSP | Dr. | Nancy | Muma | University of Washington, Seattle, WA |
| 2003 | Formation Filamentous Tau Inclusions in Human Cells with Inducible Expression of Tau Proteins | Dr. | Shu-Hui | Yen | Mayo Clinic, Jacksonville, FL |
| 2003 | Refining the Genetic and Functional Role of the Tau H1 Haplotype in Neurodegeneration | Dr. | Matt | Farrer | Mayo Clinic, Jacksonville, FL |
| 2003 | Aging Effects and Gene Therapy in a Novel Nigrostriatal Degeneration Model | Dr. | Ronald | Klein | LSU Health Sciences Center, Shreveport, LA |
| 2003 | Development and Characterization of a Novel Experimental Model of PSP | Dr. | Etienne | Hirsch | Salpetriere, Hospital de la, Paris, France |
| 2003 | Genetic Analysis of 17q21 Region Sporadic Tauopathies | Dr. | Alison | Goate | Washington University School of Medicine, St. Louis, MO |
| 2003 | Hyperphosphorylation, Tau Filaments and Neurodegeneration in a Transgenic Mouse Model of a Human Tauopathy | Dr. | Maria | Spillantini | University of Cambridge, Cambridge, UK |
| 2003 | Identification of Cis-Elements that Regulate Exon 10 Splicing in the Tau Gene | Dr. | Jianhua | Zhou | University of Massachusetts Medical School, Worcester, MA |
| 2003 | mRNA Profiling in the Postmortem PSP Brain: Target Identification | Dr. | Sarah | Augood | Massachusetts General Hospital, Boston, MA |
| 2003 | Diagnostic Protein Biomarker Discovery in PSP | Dr. | Lap | Ho | University of Washington School of Medicine, St. Louis, MO |
| 2002 | A Novel Approach for Neuroprotection in PSP | Dr. | Irene | Litvan | Henry M. Jackson Foundation, Bethesda, MD |
| 2002 | Efficacy of Environmental on a Mouse Models of Tauopathy | Dr. | Jada | Lewis | Mayo Clinic College of Medicine, Jacksonville, FL |
| 2002 | The Relationship of Guamanian Pigmentary Retinopathy to ALS/PDC of Guam | Dr. | John | Steele | Tamuning, Guam |
| 2002 | Prehistory of PSP: Bibliographic Search and Copying | Dr. | Adolfo | Brusa | Ospedalia Galliera, Italy |
| 2002 | Cross-Linking of Tau in PSP Neurofibrillary | Dr. | Nancy | Muma | Loyola University Chicago, Maywood, IL |
| 2002 | Characterization of Tau Auto-Antibodies in PSP | Dr. | James | Tetrud | The Parkinson’s Institute, Research and Treatment Center, CA |
| 2002 | Screening of Tau Mutation in a Unique PSP Family | Dr. | Rong | Chen | The Parkinson’s Institute, Basic Research, Sunnyvale, CA |
| 2002 | Analysis of the 17q21 Region in PSP, Tau Gene Analysis in Parkin’s Disease Dementia and in other Atypical Parkinsonims | Dr. | Eduardo | Tolosa | Neurology Service, Hospital Clinic, Barcelona, Spain |
| 2002 | Cortial and Striatal Cholinergic Receptor Subtypes in PSP, Alzheimer’s Disease and Dementia with Lewy Bodies | Dr. | David | Burn | Newcastle General Hospital, Regional Neuroscience Centre, UK |
| 2002 | Glial Tau Aggregates in PSP and Human Cultured Cells | Dr. | Hanna | Ksiezak-Reding | Mount Sinai School of Medicine, New York, NY |
| 2002 | Development of a Measure of Health-Related Quality of Life PSP | Dr. | Anette | Schrag | University College London, London, UK |
| 2006 | Eloise H. Troxel Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic, Jacksonville, FL |
| 2001 | Finding the Cause and Effect of a Bioenergetic Defect in PSP | Dr. | David | Albers | Cornell University, Weill Medical College, New York, NY |
| 2001 | Interaction of Parkin Protein with Abnormal Tau | Dr. | Paul | Fishman | University of Maryland School of Medicine, Baltimore, MD |
| 2001 | Characterization of the Molecular Mechanisms Leading to PSP | Dr. | Justo | Garcia de Yebenes | Fundacion Jimenez Diaz, Madrid, Spain |
| 2000 | Regulation of Human Tau Gene Expression and it’s Role in PSP | Dr. | Jane | Wu | Washington University School of Medicine, St. Louis, MO |
| 2001 | Tau Auto-Antibody Production in PSP | Dr. | James | Tetrud | The Parkinson’s Institute, Research and Treatment Center, , CA |
| 2001 | Mechanisms Regulating Neurofibrillary Tangle Formation in PSP | Dr. | Nancy | Muma | University of Washington, Seattle, WA |
| 2001 | Comparison of Region Specific MRNA Expression Profiles of PSP Brains with those of Alzheimer, FTDP-17, Pick Disease & Non Affected Brains, using DNA Microarray Technology | Dr. | Vincenzo | Bonifati | Erasmus University Rotterdam, The Netherlands |
| 2001 | mRNA Profiling in the Postmortem PSP Brain: Identifying Abnormal Signaling Pathways | Dr. | Sarah | Augood, | Massachusetts General Hospital, Boston, MA |
| 2001 | Dopa-resistant Parkinsonism in Guadeloupe: Evaluation of Isoquinolines Derivates and Acetogenines Toxicity in Rats | Dr. | Dominique | Caparros-Lefebvre | University Hospital, Guadeloupe, France |
| 2000 | Effect of Lipoperxidation on cdk5 Activity and Tau Protein Aggregation: A Model of PSP Pathogenesis | Dr. | Massimo | Tabaton | University of Genova, Department of Neurosciences, Italy |
| 2000 | Are Matrix Metalloproteinases Involved in the Pathogenesis of PSP? | Dr. | David | Albers | Cornell University, Weill Medical College, New York, NY |
| 2001 | Regulation of Human Tau Gene Expression and it’s Role in PSP | Dr. | Jane | Wu | Washington University School of Medicine, St. Louis, MO |
| 2000 | Environmental Factors and Detoxification Mechanisms in PSP | Dr. | Rosemary | Waring | The University of Birmingham, Birmingham, UK |
| 1999 | Mutational Analysis of the Tau Gene in PSP | Dr. | Joseph | Higgins | New York State Dept. of Health, New York, NY |
| 1999 | Ultrastructural and Biochemical Hetergeneity of Paired Helical Filaments in PSP | Dr. | Hanna | Ksiezak-Reding | Mount Sinai School of Medicine, New York, NY |
| 1999 | Are Impairments of Energy Metabolism Contributory in PSP? | Dr. | Flint | Beal, M. Flint, MD | Cornell University, Weill Medical College, New York, NY |
| 1999 | Activity and Expression of Antioxidant Enzymes in the PSP Brain | Dr. | Sarah | Augood | Massachusetts General Hospital, Boston, MA |
| 1999 | Problems of Cell Death in PSP | Dr. | Kurt | Jellinger | University of Vienna School of Medicine, Austria |
| 1999 | Identification of the PSP Gene | Dr. | Parvoneh | Navas | University of Washington, Seattle, WA |
| 1999 | Role of the Thalmus in PSP and Parkinson’s Disease | Dr. | Jasmine | Henderson | Prince of Wales Medical Research Institute, Randwick, Australia |
| 1999 | Is Brain Oxidative Stress & Damage Characteristic of PSP? | Dr. | Stephen | Kish | Centre for Addiction & Mental Health, Toronto, ON, Canada |
| 1999 | Mechanisms of Neurofibrillary Tangle Formation in PSP | Dr. | Nancy | Muma | Loyola University Chicago, Maywood, IL |
| 1999 | Synaptic Protein Loss and Alterations in Growth Inhibitory Factors as a Biological Foundation of Behavioural Changes & Cognitive Decline in PSP | Dr. | Elizabeth | Mukaetova-Ladinska | University of Newcastle upon Tyne, UK |
| 1998 | Neuropathological Grading Scale for PSP | Dr. | Mark | Becher | University of New Mexico, Health Science Center, Albuquerque, NM |
| 1998 | Neuroanatomical Basis for PSP Eyelid Motor Dysfunction | Dr. | Mark | LeDoux | University of Tennessee, Memphis, TN |
| 1998 | Mitochondria in PSP | Dr. | Russell | Swerdlow | University of Virginia School of Medicine, Charlottesville, VA |
| 1998 | Tau Gene Mutations in PSP | Dr. | Joseph | Higgins | Laboratory of Clinical Neurogenetics, Wadsworth Center, Albany, NY |
| 1998 | Oxidative Mechanisms in PSP | Dr. | David | Albers | Massachusetts General Hospital, Neurology Dept., Boston, MA |
| 1998 | Molecular Studies of the Tau Gene in PSP | Dr. | William | Johnson | Robert Wood Johnson Medical School, New Brunswick, NJ |
| 1998 | Potential Role of Mitochondrial Defects in PSP | Dr. | Flint | Beal | Cornell University, Weill Medical College, New York, NY |
| 1998 | Trial of Donepezil HCL in PSP Patients | Dr. | Irene | Litvan | Henry M. Jackson Foundation, Bethesda, MD |
| 1998 | Establishment of a PSP Brain Bank | Dr. | Dennis | Dickson | Mayo Clinic, Jacksonville, FL |
| 1997 | Haplotype Relative Risk Analysis in PSP | Dr. | Lawrence | Golbe | Robert Wood Johnson Medical School, New Brunswick, NJ |
| 1997 | The History of PSP | Dr. | Adolfo | Brusa | Corso A. Saffi, Genoa, Italy |
| 1997 | Reaction Time and Acoustic Startle in Patients with PSP, Multi-System Atrophy, Barcelona and Parkinson’s Disease | Dr. | Josep | Valls-Sole | Hospital Clinic, Barcelona, Spain |
| 1997 | Linkage Analysis in Familial PSP (To Perform Linkage Analysis in a Large Spanish Family with PSP) | Dr. | Justo | Garcia de Yebenes | Universidad Autonoma de Madrid, Madrid, Spain |
| 1997 | Ferritin is Associated with the Aberant Tau Filaments Present in PSP | Dr. | Jesus | Avila | Centro De Biologica Molecular, Madrid, Spain |
| 1997 | Genetics and Environmental Studies of Bodig and Lytico in Villages of Southern Guam | Dr. | John | Steele | Tamuning, Guam |
| 1997 | Presence and Amount of Glycation & Oxidation Markers in PSP | Dr. | Massimo | Tabaton | University of Genova, Italy |